0000899243-18-018711.txt : 20180629 0000899243-18-018711.hdr.sgml : 20180629 20180629160108 ACCESSION NUMBER: 0000899243-18-018711 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180627 FILED AS OF DATE: 20180629 DATE AS OF CHANGE: 20180629 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ross Leonard S CENTRAL INDEX KEY: 0001458753 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 18929273 MAIL ADDRESS: STREET 1: C/O PSIVIDA CORP STREET 2: 400 PLEASANT STREET CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-27 0 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001458753 Ross Leonard S C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 0 1 0 0 See Remarks Common Stock 2018-06-27 4 M 0 6666 A 16666 D Common Stock 2018-06-27 4 F 0 1904 1.86 D 14762 D Restricted Stock Units 2018-06-27 4 M 0 6666 0.00 D Common Stock 6666 13334 D Restricted stock units convert into common stock on a one-for-one basis. On June 27, 2017, the reporting person was granted 20,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the insider's exercise of his withholding right following the vesting of the restricted stock units. Vice President of Finance and Chief Accounting Officer /s/ John Mercer, Attorney-in-Fact 2018-06-29